Drug Safety
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Dr. John Cush RheumNow
4 years ago
Video: Combination DMARD for Lupus Nephritis: Dr. Kathryn Dao ( @KDAO2011 )
#EULAR2021
https://t.co/RGVZ6jukYy https://t.co/PTjSOfM7YQ
Dr. John Cush RheumNow
4 years ago
Video: The PsA SpA Paradox of Choice
Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting.
https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
Dr. John Cush RheumNow
4 years ago
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 mg till wk 12
-TP2: cont SEC or switch to PBO till wk 104
⭐️SEC efficacious on JIA ACR30/70
⭐️74% w/ resolution of enthes
⭐️Median T2flare in PBO in TP2 = 453d
LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Robert B Chao, MD doctorRBC
4 years ago
Excellent talk on SLE, APS abs pregancy
⭐️pregnancy counseling is important
⭐️aspirin 81mg in all pregnant SLE pts
⭐️do not discontinue HCQ
⭐️stable LN - can switch MMF to AZA
Abs#6888
#EULAR2021 @RheumNow
Paul Studenic Stiddyo
4 years ago
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear.
Head to head JAK-i vs. non-TNFi interesting
Brilliant developing discussion
number needed to harm vs. number needed to treat
#EULAR2021 @RheumNow
Dr. John Cush RheumNow
4 years ago
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Poster Hall